July 12, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has entered into a License Agreement with Mabwell Pharmaceuticals, China, the latest company’s filing showed.
Under this agreement, the company will manufacture, register, and market the Denosumab Biosimilars drugs in Pakistan.
This partnership will benefit the patients in Pakistan by providing high quality affordable biological medicines.
“The company is committed to increasing its portfolio of products and business which will enhance the quality of its earnings and shareholders' value,” It reads.
Mabwell Pharmaceuticals is an innovative biopharmaceutical company.
Copyright Mettis Link News
Posted on:2023-07-12T15:09:48+05:00
39136
